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Abstract 
 
Purpose: To determine whether radical prostatectomy (RP) or intensity 
modulated radiation therapy (IMRT) to ≥72 Gy, plus hormonal therapy if 
indicated, results in improved biochemical disease free survival (BDFS) in 
localized prostate adenocarcinoma. 
 
Methods and Materials: Between 1997-2005, a consecutive sample of 556 
patients who underwent RP (n=204) or IMRT (n=352) at two referral centers was 
analyzed. Patients were stratified into prognostic groups based on clinical stage, 
Gleason score, and pretreatment prostate specific antigen (PSA) level as 
outlined by schemes designed by Memorial Sloan Kettering (MSK) and the 
National Comprehensive Cancer Network (NCCN). The outcome used in this 
study was BDFS. Median follow up in the RP and IMRT cohorts was 46 months 
and 40 months, respectively. 
 
Results: IMRT patients had more advanced and aggressive disease at baseline 
(p<.001). No difference was found in five-year BDFS rates between RP and 
IMRT in the favorable prognosis (92.8% vs. 85.3%, p=.20) or the MSK 
intermediate prognosis (86.7% vs. 82.2%, p=.46) subsets. A difference favoring 
IMRT was seen in the NCCN intermediate prognosis (70.7% vs. 83.3%, p=.03), 
MSK poor prognosis (38.4% vs. 62.2%, p<.001), and NCCN poor prognosis 
(37.0% vs. 56.8%, p=.005) subsets. Within the entire cohort, after adjustment for 
 iii 
confounding variables, Gleason score (p<.001) and clinical stage (p<.001) 
predicted BDFS, but treatment modality (p=.06) did not. Within the MSK poor 
prognosis subset, treatment modality (p=.006) was predictive of BDFS, favoring 
IMRT. 
 
Conclusion: Biochemical disease free survival is similar between RP and IMRT 
for patients with a good prognosis. Patients with a poor prognosis, and some with 
an intermediate prognosis, may benefit from IMRT to ≥72 Gy plus hormonal 
therapy.  
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 1 
Introduction 
 
Prostate cancer is second only to nonmelanoma skin cancer as the most 
common form of cancer in American men and it is estimated that 218,890 
American men were diagnosed with prostate cancer in 2007.1 Prostate cancer 
represents the second leading cause of cancer-related death in American men, 
accounting for an estimated 27,050 deaths in 2007.1 Over the past two decades, 
prostate cancer has become more commonly diagnosed at earlier stages of 
disease, likely due to the increased availability of prostate specific antigen (PSA) 
assays.2 Currently, over 80% of newly diagnosed prostate cancer patients have 
clinically localized disease,3 and as a result the number of men receiving local 
treatment with curative intent has increased.4 
 Treatment of patients diagnosed with localized prostate cancer (T1-
T3N0M0)5 centers around one of four options: observation, radical prostatectomy 
(RP), external beam radiation therapy, or brachytherapy. Observation alone has 
been shown in a prospective, randomized, controlled study to yield inferior 
outcomes when compared to surgery.6, 7 This study randomized 695 men with 
stage T1-T2 prostate cancer (i.e., cancer confined to the prostate) to either RP or 
observation. With a median follow up of 8.2 years, RP yielded a statistically 
significant improvement in overall survival and disease-specific survival when 
compared to observation alone.6, 7 As a result, observation is generally only 
appropriate for older patients with significant comorbidities and limited life 
expectancy, as these patients may not be candidates for more aggressive 
treatment, such as surgery or radiation. However, the debate regarding 
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observation versus treatment in patients with very early, localized, non-
aggressive (i.e., low Gleason score and PSA levels) cancer continues.8, 9  
Only patients with early, low-grade cancers are candidates for 
brachytherapy alone, as several series have reported poorer outcomes in 
patients with a clinical stage greater than T2a (i.e., the tumor can be palpated in 
less than half of one of the prostate gland's two lobes), a Gleason score of 
greater than 6, or a pretreatment PSA of greater than 10 ng/mL.10, 11 In a 
retrospective study, which examined 1872 men treated with either RP, 
brachytherapy, or external beam radiation therapy, brachytherapy was found to 
yield statistically worse rates of biochemical control in patients with a clinical 
stage of T2b or greater, a Gleason score of greater than 6, or a pretreatment 
PSA of greater than 10 ng/mL when compared to the other two treatment 
modalities.11 Other retrospective studies12 and systematic reviews13 have found 
similar results.  
Unlike brachytherapy or observation, RP and external beam radiation 
therapy (with or without hormonal therapy) are appropriate options for almost all 
patients with localized prostate cancer, regardless of clinical stage, Gleason 
score, or pretreatment PSA.10, 14 To date, only one prospective trial has been 
performed comparing RP and external beam radiation therapy in American 
men.15 The trial was published in 1982 and included 97 patients, all with T1-T2 
disease (i.e., disease confined to the prostate). Forty one patients were 
randomized to RP and 56 patients were randomized to external beam radiation 
therapy. This trial found that RP yielded higher progression-free survival than 
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external beam radiation therapy at five years post-therapy (p=.04). However, this 
study is now outdated and was limited by numerous methodological flaws.16-18 
Some physicians who enrolled patients in the trial did not use the specified 
randomization scheme, raising concern for physician selection bias. The study 
permitted cross-over between treatment arms and the analysis was not done on 
an intent-to-treat basis; rather, the analysis was based on the actual treatment 
given, which generally is not standard practice when designing randomized trials. 
Pathologic stage C patients (i.e., those with the poorest prognosis) were 
excluded from the surgical arm but allowed in the radiation arm and a worse than 
previously reported outcome was seen among external beam radiation therapy 
patients. Additionally, the authors did not provide data as to the pretreatment 
characteristics of each cohort (e.g. Gleason score, acid phosphatase level, age, 
race etc…), and no multivariable analysis was performed. A multivariable 
analysis would be necessary to account for the impact of clear differences in the 
respective cohorts, such as the pathologic stage of patients included in the study. 
As a result of these limitations, it is difficult to form any meaningful conclusions 
regarding RP versus external beam radiation therapy in the treatment of localized 
prostate cancer based on this single trial.16-18 
 A number of retrospective reviews have attempted to compare RP and 
external beam radiation therapy.11, 19-25 Of the contemporary reviews (i.e., those 
published in the past twelve years, in which all patients received PSA follow up), 
all used biochemical disease free survival (BDFS) as the primary outcome 
measure. Nearly all studies stratified patients based on the proven prognostic 
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factors of pretreatment PSA, Gleason score, and clinical stage. Patients treated 
with surgery almost always underwent a radical retropubic prostatectomy, often 
times with a lymph node dissection, while patients treated with external beam 
radiation therapy frequently were treated via a conformal technique. Radiation 
doses ranged from a median of 66 Gy to a median of 70.2 Gy, with the exception 
of the review by Keyser et al.19 in which the median dose of radiation was 74 Gy 
(range 70 Gy to 83 Gy).   
Most prior retrospective reviews found no difference in outcome between 
RP and external beam radiation therapy in all prognostic groups,11, 19-21, 24 with 
the following exceptions. A review by D’Amico et al. found improved BDFS in 
patients who underwent a radical prostatectomy, as opposed to external beam 
radiation therapy, if they had a favorable prognosis (defined as patients with a 
pretreatment PSA of 10 ng/mL or less, a Gleason score of 6 or less, and a 
clinical stage of T2a or less) or an intermediate prognosis (defined as patients 
with a pretreatment PSA of greater than 10 ng/mL but less than 20 ng/mL, a 
Gleason score of 7, or a clinical stage of T2b), provided that these patients 
carried a low tumor volume (defined as <34% of positive biopsies). However, in 
patients with an intermediate prognosis, the difference in outcome was no longer 
significant at 10 years post therapy.  
In a retrospective review by Kupelian et al., initial analysis revealed no 
difference in BDFS in any prognostic group. However, on subgroup analysis of 
patients with a poor prognosis (defined as a pretreatment PSA of greater than 10 
ng/mL, a Gleason score of 7 or greater, or a clinical stage of T2b or greater), 
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patients who received external beam radiation therapy to a dose of at least 72 Gy 
had significantly better BDFS when compared to patients who underwent RP 
(p=.004), while patients treated with external beam radiation therapy to a dose 
less than 72 Gy had significantly poorer BDFS than patients who underwent RP 
(p<.001).22 A subsequent retrospective study by Kupelian et al. also found that 
external beam radiation therapy to a dose of less than 72 Gy yielded inferior 
biochemical disease free survival when compared to RP. This result was seen in 
the whole cohort and among each prognostic group.23  
Collectively, these retrospective studies seem to indicate that RP and 
external beam radiation therapy generally yield similar outcomes in patients with 
prostate cancer, but also that the dose of radiation used to treat patients may 
impact the results of the trial. 
Since the last study comparing RP and external beam radiation therapy 
was carried out, novel strategies in the management of localized prostate cancer 
have been adopted by the oncology community. The standard of care for 
external beam radiation therapy now centers on a relatively new approach, 
intensity modulated radiation therapy (IMRT).26-29 IMRT, which became widely 
available 5-10 years ago, offers the ability to modulate individual beams of 
radiation so that the intensity of photons within a particular beam can be varied. 
This facilitates the ability to deliver high doses of radiation to the tumor, while 
administering relatively low doses of radiation to surrounding tissues, such as the 
bowel and bladder in cases of prostate cancer.30 High doses of radiation (those 
exceeding 72 Gy) have been decidedly shown to improve outcomes in patients 
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with prostate cancer31-33 (as suggested by the retrospective studies comparing 
RP and external beam radiation therapy), and IMRT is the preferred radiotherapy 
technique because its lower side effect profile, compared to other forms of 
external beam radiation therapy, allows higher doses of radiation to safely be 
used in the treatment of prostate cancer.23, 34-36 With non-IMRT based 
approaches, it may not be feasible to safely deliver high doses of radiation to the 
prostate without exceeding the tolerance of the surrounding bowel and bladder, 
thereby resulting in serious acute and late radiation toxicity.37, 38 To date, no 
study has compared IMRT to RP in the treatment of prostate cancer. In addition, 
no previous review has only included patients treated to 72 Gy or higher, now 
considered the standard of care.39 
Since the publication of the last retrospective review comparing RP to 
external beam radiation therapy, hormonal therapy has become a mainstay 
adjunctive treatment for patients with an intermediate or poor prognosis when 
given in conjunction with radiation.40-44 In Radiation Therapy Oncology Group 
Trial 8610, patients were randomized to external beam radiation with or without 
four months of goserelin (a gonadotropin releasing hormone agonist) plus 
flutamide (an androgen receptor antagonist) in the neoadjuvant/concurrent 
setting. At a median follow up of 12.5 years, the cohort randomized to hormonal 
therapy displayed decreased disease-specific mortality, distant metastases, and 
biochemical failures.45 Another prospective trial randomized locally advanced 
prostate cancer patients to either external beam radiation alone or radiation plus 
three years of concurrent/adjuvant goserelin plus one month of cyproterone (an 
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androgen receptor antagonist). At a median follow up of 66 months, hormonal 
therapy significantly improved disease free survival and overall survival.46, 47 
Other prospective studies have found similar results.48 As a result, hormonal 
therapy is generally indicated in patients treated with external beam radiation 
therapy who have an intermediate or poor prognosis (i.e., patients with a 
pretreatment PSA of greater than 10 ng/mL, a Gleason score of greater than 6, 
or a clinical stage of greater than T2a); hormonal therapy is not indicated in 
patients who undergo surgery because no benefit has been seen in surgical 
patients who undergo adjuvant hormonal therapy.40, 48, 49  
In all previous reviews, patients receiving hormonal therapy were excluded 
from the analysis19-21, 24, 25 or only a small percentage of patients in the review 
received hormonal therapy. Specifically, in a review published by Kupelian et al., 
17% of RP patients and 23% of external beam radiation therapy patients 
received hormonal therapy. In another review by Kupelian et al. 17% of RP 
patients and 5-39% of external beam radiation therapy patients (depending on 
prognostic group) received hormonal therapy.22, 23 In all other retrospective 
studies cited in this thesis, no patients were treated with hormonal therapy. 
Another limitation of prior retrospective studies comparing RP and external 
beam radiation therapy pertains to the varying definitions of "post-treatment 
biochemical failure" used in each review. Although all definitions of post-
treatment biochemical failure are based on PSA levels,50 each definition carries a 
different sensitivity and specificity for true clinical failure.51-53 Therefore, it is 
difficult to interpret the results of previous retrospective studies. For example, of 
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the aforementioned retrospective reviews comparing RP to external beam 
radiation therapy, four definitions of post-RP biochemical failure were used 
including “two PSA levels of greater than 0.2 ng/mL”,22-24 “two detectable PSA 
levels”,20 “a single PSA of at least 0.2 ng/mL”,19, 21 and “three consecutive PSA 
rises”.11, 25 Post external beam radiation therapy definitions have varied as well 
and have included “three consecutive rises in PSA level”,11, 21-25 “two consecutive 
rises in PSA level”,20 and “PSA nadir plus one ng/mL”.19 To combat this problem, 
in 2006 the American Society for Therapeutic Radiology and Oncology (ASTRO) 
published guidelines recommending that the definition of post-external beam 
radiation therapy biochemical failure be established as absolute PSA nadir + 2 
ng/mL.54 No retrospective study has used this definition of post external beam 
radiation therapy biochemical failure. Another benefit of the updated definition of 
post-external beam radiation therapy biochemical failure is that it can be applied 
if a patient receives external beam radiation therapy and hormonal therapy, 
which is not the case with previous definitions because data used to derive these 
definitions was obtained from patients who were not treated with hormonal 
therapy.54 For patients treated with RP, the American Urological Association 
(AUA) guidelines, published in 2007, define post-treatment failure as a single 
PSA of 0.2 ng/mL, with a second confirmatory PSA exceeding 0.2 ng/mL.55 No 
review has used this definition of post-RP failure, although many have used 
similar definitions.  
The primary goal of this study was to retrospectively compare radical 
prostatectomy to dose-adequate intensity modulated radiation therapy plus 
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hormonal therapy, if indicated, in patients with localized prostate cancer, using 
modern definitions of biochemical disease free survival as the outcome measure. 
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Hypothesis and Specific Aims 
 
The primary goal of this study was to retrospectively compare radical 
prostatectomy to dose-adequate intensity modulated radiation therapy plus 
hormonal therapy, if indicated, in patients with localized prostate cancer, using 
modern definitions of biochemical disease free survival as the outcome measure. 
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Methods and Materials 
 
Study Design and Patient Populations 
 
We conducted a retrospective observational cohort study of a consecutive 
sample of 708 patients treated for localized prostate adenocarcinoma between 
1997-2005; 495 patients received radiation therapy and 213 underwent surgery. 
Patients receiving post-operative radiation were excluded from the study. 
Patients treated with radiation therapy received treatment at either Yale New 
Haven Hospital (New Haven, CT, 373 patients) or Lawrence & Memorial Hospital 
(New London, CT, 122 patients).  All 213 patients treated surgically underwent a 
radical retropubic prostatectomy at Yale New Haven Hospital. Patients were 
excluded from the IMRT group if they lacked three post-treatment PSA levels 
(n=97), were treated to doses under 72 Gy (n=45), or lacked adequate 
pretreatment staging (n=1), leaving 352 patients in the IMRT group. Patients 
were excluded if they lacked three post-treatment PSA values because of the 
inability to apply the “nadir + 2” definition of failure in such cases. Patients were 
excluded from the RP cohort if they lacked an accessible follow up PSA (n=7) or 
underwent a salvage prostatectomy after failed radiation therapy (n=2), leaving 
204 patients in the RP cohort.  
 
Staging 
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Before receiving therapy, all patients underwent a clinical history and 
physical including digital rectal examination, PSA level, and ultrasound guided 
transrectal prostate biopsy with Gleason score histological grading. Other staging 
modalities such as computed tomography of the pelvis, magnetic resonance 
imaging of the prostate or pelvis, positron emission tomography, or bone 
scanning were performed at the discretion of the attending physician. No patient 
was found to have metastatic disease after staging evaluation.  Staging was 
performed in accordance with the 1992 AJCC staging system.5 A summary of the 
AJCC clinical staging of prostate cancer, as presented by the National Cancer 
Institute, is presented below: 
TX: Primary tumor cannot be assessed  
T0: No evidence of primary tumor  
T1: Clinically unapparent tumor not palpable nor visible by imaging  
T1a: Tumor incidental histological finding in 5% or less of tissue resected  
T1b: Tumor incidental histological finding in more than 5% of tissue  
resected  
T1c: Tumor identified by needle biopsy (e.g., because of elevated PSA)  
T2: Tumor confined within prostate  
T2a: Tumor involves 50% or less of one lobe  
T2b: Tumor involves more than 50% of one lobe but not both lobes  
T2c: Tumor involves both lobes  
T3: Tumor extends through the prostate capsule  
T3a: Extracapsular extension (unilateral or bilateral)  
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T3b: Tumor invades seminal vesicle(s)  
T4: Tumor is fixed or invades adjacent structures other than seminal vesicles:  
bladder neck, external sphincter, rectum, levator muscles, and/or pelvic wall  
 
Prognostic Groups 
 
Patients were stratified into prognostic groups based on the prognostic 
parameters of clinical stage, Gleason score, and PSA level. Each of these 
prognostic factors independently predicts outcome in patients with prostate 
cancer.56-60 Two prognostic group schemes were chosen; these appear to be the 
schemes most commonly used by clinicians in practice.3, 19, 20, 23, 61 
In the Memorial Sloan Kettering (MSK) scheme,62, 63 the favorable 
prognosis group consisted of patients with a clinical stage ≤T2a, a Gleason score 
≤6, and a pretreatment PSA ≤10 ng/mL. Patients in the intermediate and poor 
prognosis groups presented with one and two or more unfavorable prognostic 
parameters (clinical stage >T2a, Gleason score >6, or PSA>10), respectively.  
The data were also analyzed using the National Comprehensive Cancer 
Network (NCCN) scheme,64 in which the favorable prognosis group also 
consisted of patients with a clinical stage ≤T2a, a Gleason score ≤6, and a 
pretreatment PSA ≤10. The intermediate prognosis group contained patients with 
a clinical stage of T2b-T2c, a Gleason score of 7, or a pretreatment PSA 
between 10-20 ng/mL. The poor prognosis group consisted of patients with a 
clinical stage of ≥T3a, a Gleason score ≥8, or a pretreatment PSA of >20 ng/mL.  
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Treatment 
 
Patients who opted for surgery underwent radical retropubic 
prostatectomy with bilateral lymph node dissection. Nearly all of the surgeries 
were performed by the same surgeon, an experienced urologic oncologist 
practicing at Yale New Haven Hospital, a tertiary care medical center.  
The vast majority (96.3%) of patients opting for radiation received exactly 
75.6 Gy in 1.8 Gy fractions (others treated to 72.0 - 77.4 Gy). Radiation was 
delivered with an isocentric, five-field technique, using 18 MV or 10 MV photons. 
IMRT was utilized, at least in part, to treat all patients undergoing radiation; 112 
patients (31.8%) received 3D conformal radiation therapy (3DCRT) and IMRT, 
203 patients (57.7%) received IMRT alone, and 37 patients (10.5%) received 
four-field whole pelvic radiation with an IMRT guided boost to the prostate.  
Patients treated with 3DCRT and IMRT were treated to 66.6 Gy with 
3DCRT using a planning target volume (PTV) defined as a 1.5 cm margin around 
the tumor volume (TV) in three dimensions, followed by a 9.0 Gy IMRT based 
cone down using a margin of 1.0 cm around the tumor volume, except for the 
rectal-prostate interface, where a 0.6 cm margin was used. Patients treated with 
IMRT alone were treated to 66.6 Gy with IMRT using a PTV defined as a 1.2 cm 
margin around the tumor volume in three dimensions, followed by a 9.0 Gy IMRT 
based cone down using a margin of 1.0 cm around the tumor volume, except for 
the rectal-prostate interface, where a 0.6 cm margin was used.  
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Whole pelvic radiation patients received 45.0 Gy to the whole pelvis with a 
30.6 Gy IMRT based cone down as described above. To deliver whole pelvic 
radiation, a four-field technique utilizing bony landmarks was employed. A four-
field technique was chosen, as opposed to an IMRT-based plan, because of data 
suggesting that IMRT does not improve lymph node coverage in advanced 
prostate cancer.65 Whole pelvic radiation was designed to cover the obturator, 
internal iliac, external iliac, pre-sacral, and peri-rectal nodes, as these are the 
most common lymph node groups involved in prostate cancer.65 The superior, 
lateral, and inferior borders of the whole pelvic field were at L5/S1, 2.0 cm lateral 
to the pelvic brim, and 0.5 cm inferior to the obturator foramen, respectively.66 
The inferior border employed in our study has been shown to adequately cover 
the apex of the prostate.67 The decision to administer whole pelvic radiation was 
made at the discretion of the attending physician. Commonly, patients with at 
least a 15% likelihood of lymph node involvement, as predicted by the Roach 
formula,68 were considered for whole pelvic radiation therapy. The Roach formula 
accounts for Gleason score and pretreatment PSA in ascertaining the likelihood 
of lymph node involvement and is presented here: 
 
% likelihood of lymph node involvement = 2/3*(PSA) + 10*(Gleason score-6) 
 
Within the IMRT group, 30 patients in the MSK favorable prognosis group 
(37.5%), 138 patients in the intermediate prognosis group (89.0%), and 114 
patients in the poor prognosis group patients (97.4%) received hormonal therapy, 
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consisting of a gonadotropin releasing hormone agonist in 56.5% of patients, an 
androgen receptor antagonist in 3.6% of patients, and combined modality 
therapy in 39.9% of patients. Patients in the intermediate and poor prognosis 
groups generally received 6 months and 12-24 months of hormonal therapy, 
respectively. After treatment, patients were followed up routinely with PSA testing 
and digital rectal exams. Follow-up visits typically occurred one month after 
completion of treatment, every 3-6 months for the following two years, and every 
6-12 months thereafter. The median follow up was 46 months in the RP cohort 
and 40 months in the IMRT cohort.  
 
Verification of Data  
  
We employed methods recommended in the literature to ensure the 
validity and reliability of data collected.69 Upon completion of data collection, a 
second reviewer blindly reabstracted a random sample of 30 charts, representing 
5.4% of the 556 charts reviewed.  The overall mean percentage agreement 
between the two reviewers was 100% across all variables.  To measure interrater 
agreement for nominal variables, a kappa statistic was calculated and found to 
be 1.0.  
 
Statistical Methods 
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Baseline patient characteristics were compared using the chi-square test 
for categorical variables and the unpaired t-test for continuous variables. If a 
categorical variable contained less than five patients, Fisher’s exact test was 
used instead.  
Biochemical failure was defined in IMRT patients as absolute PSA nadir + 
2 ng/mL. The date of failure was defined as the date at which the post-treatment 
PSA exceeded the nadir + 2 ng/mL. Post-RP biochemical failure was defined as 
a single PSA of at least 0.2 ng/mL, with a second confirmatory PSA of greater 
than 0.2 ng/mL. The date of failure was defined as the date at which the PSA 
reached 0.2 ng/mL. Data was censored at the date of last PSA level. The data 
were not analyzed with alternative definitions of biochemical failure or with an 
alternative prognostic group scheme.  
Biochemical disease free survival was calculated using the Kaplan-Meier 
method, graphically displayed, and compared with the log-rank test. Biochemical 
disease free survival rates at individual post-treatment times were compared by 
calculating the quotient of the difference in survival (between RP and IMRT 
cohorts at a given time point) squared and the weighted variance of the survival 
functions, and subsequently comparing this quotient to the chi-square distribution 
using one degree of freedom.70  
With the use of proportional hazards analysis, hazard ratios and 95% 
confidence intervals were generated for the unadjusted association between 
baseline characteristics and biochemical failure. To examine the impact of 
confounding factors, a Cox proportional hazards multivariate analysis was 
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performed using the following variables: age, race, prior transurethral resection of 
the prostate (TURP), clinical stage, Gleason score, pretreatment PSA, treatment 
modality (RP vs. IMRT), type of radiation therapy employed, hospital of 
treatment, and hormonal therapy. To remain in the model, variables were 
required to have a p value of <.20.  
All reported p values are two-sided. Statistical analysis was performed 
using SAS version 9.1. This study was approved by the Institutional Review 
Board of Yale School of Medicine. The study was carried out in a manner 
consistent with the Helsinki Declaration of 1975, as revised in the year 2000. 
Written consent was not obtained from participants (i.e., a waiver was granted) 
because this was a retrospective review of existing patient data. 
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Results 
 
Patient Characteristics 
 
Pretreatment and treatment-related patient characteristics are 
summarized by treatment modality in Table 1.  
 
Table 1. Pretreatment and Treatment-Related Patient Characteristics 
Pretreatment Parameter RP patients IMRT patients All patients P 
                  
    N % N % N %   
Age               <.001 
  ≤65 179 88 100 28 279 50   
  >65 25 12 252 72 277 50   
Race               0.27* 
  White 174 85 284 81 458 82   
  
African 
American 29 14 62 18 91 16   
  Asian 0 0 4 2 4 1   
  Hispanic 1 0.5 2 1 3 1   
Prior TURP               <.001 
  Yes  2 1 23 7 25 4   
  No 202 99 329 93 531 96   
Clinical 
Stage               0.01† 
  T1-T2a 152 75 294 84 446 80   
 21 
  T2b-T2c 51 25 31 9 82 15   
  T3a 1 0.5 26 7 27 5   
  T3b 0 0 1 0.3 1 0.2   
Gleason 
Score (total)               <.001 
  ≤6 144 71 126 36 270 49   
  7 49 24 145 41 194 35   
  ≥8 11 5 81 23 92 17   
Pretreatment 
PSA               <.001 
  ≤4 29 14 28 8 57 10   
  >4 to ≤10 138 68 191 54 329 51   
  >10 to ≤20 29 14 89 25 118 29   
  >20 8 4 44 13 52 9   
MSK 
Prognosis 
Group               <.001 
  Favorable 103 50 80 23 183 33   
  Intermediate 59 29 155 44 214 38   
  Poor 42 21 117 33 159 29   
NCCN 
Prognosis 
Group               <.001 
  Favorable  103 50 80 23 183 33   
  Intermediate 84 41 150 43 234 42   
  Poor 17 8 122 35 139 25   
Method of 
Radiation               n/a 
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  3DCRT+IMRT n/a   112 32 n/a     
  IMRT alone n/a   201 57 n/a     
  
Whole Pelvic 
IMRT n/a   39 11 n/a     
Treatment 
Site               <.001 
  
Lawrence & 
Memorial 
Hospital 0 0 71 20 71 13   
  
Yale New 
Haven 
Hospital 204 100 281 80 485 87   
Hormonal 
Therapy               <.001 
  Yes  6 3 282 80 288 52   
  No 198 97 70 20 268 48   
*p value represents Chi-Square between White patients and African 
American patients 
†p value represents Chi-Square for clinical stage ≤ T2a vs. >T2a 
 
Abbreviations: RP = Radical Prostatectomy; IMRT = Intensity Modulated 
Radiation Therapy; 3DCRT = 3 Dimensional Conformal Radiation 
Therapy; PSA = Prostate Specific Antigen; MSK = Memorial Sloan 
Kettering; NCCN = National Comprehensive Cancer Network; TURP = 
Transurethral Resection of the Prostate 
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Patients in the IMRT group were older, and had higher Gleason scores 
and pretreatment PSA levels, than patients in the RP group (p<.001 in all cases). 
Although more RP patients had a clinical stage ≥T2b (p=.01), more IMRT 
patients had T3 disease (p<.001). Patients in the IMRT cohort had more 
advanced disease, as judged by both the MSK and NCCN prognostication 
schemes (p<.001). There was no significant difference in race between RP and 
IMRT cohorts.   
 
Treatment Outcome 
 
Three-year and five-year biochemical disease free survival rates for the 
combined and individual prognostic groups are displayed in Table 2.  
 
Table 2. Biochemical Disease Free Survival Rates in RP and IMRT Patients 
Cohort   3 yr BDFS 95% CI p 5 yr BDFS 95% CI p 
                
Whole cohort       0.004     0.37 
  RP 83.5 76.9-88.3   78.4 70.5-84.3   
  IMRT 91.7 87.7-94.5   74.8 66.2-81.5   
MSK favorable       0.45     0.20 
  RP 95.1 87.4-98.1   92.8 83.0-97.1   
  IMRT 97.3 89.7-99.3   85.3 68.6-93.5   
MSK inter       0.13     0.46 
  RP 86.7 72.4-93.9   86.7 72.4-93.9   
  IMRT 94.0 88.2-97.0   82.2 69.3-90.1   
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MSK poor       <.001     <.001 
  RP 53.8 36.8-68.0   38.4 21.8-54.8   
  IMRT 85.8 76.8-91.6   62.2 47.0-74.3   
NCCN 
favorable*       0.45     0.20 
  RP 95.1 87.4-98.1   92.8 83.0-97.1   
  IMRT 97.3 89.7-99.3   85.3 68.6-93.5   
NCCN inter       0.002     0.03 
  RP 77.5 65.7-85.6   70.7 57.2-80.6   
  IMRT 91.7 85.0-95.5   83.3 72.0-90.4   
NCCN poor       <.001     0.005 
  RP 49.3 23.0-71.2   37.0 11.6-63.1   
  IMRT 88.0 79.3-93.3   56.8 39.4-71.0   
*The favorable prognosis group in the MSK and NCCN prognostication schemes 
consists of the same patients. 
 
Abbreviations: RP = Radical Prostatectomy; IMRT = Intensity Modulated Radiation 
Therapy; MSK = Memorial Sloan Kettering; NCCN = National Comprehensive Cancer 
Network; CI = Confidence Interval 
 
No significant difference in biochemical disease free survival was 
observed between RP and IMRT at any time point within the MSK/NCCN 
favorable and the MSK intermediate prognosis subsets. Differences in 
biochemical disease free survival favoring the IMRT group were seen in the MSK 
poor prognosis subset at three (p<.001) and five (p<.001) years post-treatment, 
the NCCN poor prognosis subset at three (p<.001) and five (p=.005) years post-
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treatment, and the NCCN intermediate prognosis subset at three (p=.002) and 
five (p=.03) years post-treatment.  
 Kaplan-Meier curves comparing biochemical disease free survival in RP 
and IMRT patients are displayed in Figure 1:  
 
 
 
 
 
 
 
Figure 1: Biochemical Disease Free Survival Rates for Whole Cohort and 
Individual Prognostic Groups 
Whole Cohort (Figure 1a) 
MSK/NCCN Favorable Prognostic 
Group (1b) 
 
MSK Intermediate Prognostic Group 
(1c) MSK Poor Prognostic Group (1d) 
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Legend: Biochemical disease free survival in RP and IMRT patients in the whole 
cohort (a), MSK/NCCN favorable prognosis group (b), MSK intermediate 
prognosis group (c), MSK poor prognosis group (d), NCCN intermediate 
prognosis group (e), and NCCN poor prognosis group (f).  
 
No significant difference in survival curves was seen in the overall study 
population, MSK/NCCN favorable prognosis subset, or MSK intermediate 
prognosis subset. Patients in the MSK poor prognosis subset (p<.001), NCCN 
intermediate prognosis subset (p=.03), and NCCN poor prognosis subset 
(p=.004) displayed higher biochemical disease free survival when treated with 
IMRT. 
 An unadjusted analysis and Cox proportional hazards multivariable 
(adjusted) analysis of the entire study population are shown in Table 3. 
 
  
NCCN Intermediate Prognostic 
Group (1e) NCCN Poor Prognostic Group (1f) 
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Table 3. Unadjusted and Adjusted Analysis of Patient Characteristics 
and Biochemical Failure for Entire Cohort 
Clinical 
Parameter† 
Unadjusted 
p value 
Unadjusted 
Hazard 
Ratio 95% CI 
Adjusted 
p value 
Adjusted 
Hazard 
Ratio 95% CI 
              
Age 0.68 1.00 0.97-1.02       
Race* 0.51 1.19 0.70-2.03       
Prior TURP 0.40 1.83 0.44-7.52       
Clinical 
Stage <.001 3.60 2.34-5.53 <.001 2.42 1.52-3.85 
Gleason 
Score (total) <.001 2.19 1.66-2.90 <.001 2.02 1.47-2.79 
Pretreatment 
PSA 0.009 1.42 1.09-1.83 0.19 1.20 0.92-1.56 
Treatment 
Modality 0.74 0.93 0.59-1.45 0.06 0.62 0.38-1.03 
Method of 
Radiation†† 0.08 0.55 0.28-1.06       
Treatment 
Site††† 0.43 1.42 0.60-3.35       
Hormonal 
Therapy 0.02 1.64 1.07-2.52       
*only Whites and African Americans were compared in 
this analysis 
† Coding of clinical parameters: Age (continuous, per year), Race (reference = white), 
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Prior TURP (reference = no TURP), Clinical Stage (T1-T2a versus T2b-T2c versus 
T3a-T3b, reference = T1-T2a), Gleason Score (<7 versus 7 versus >7, reference = 
<7), Pretreatment PSA (continuous, per ng/mL increment), Treatment Modality 
(reference = RP), Method of Radiation (reference = 3DCRT + IMRT), Treatment Site 
(reference = Lawrence & Memorial Hospital), Hormonal Therapy (reference = no 
hormonal therapy)   
††only 3DCRT+IMRT and IMRT alone were compared in this analysis 
†††only includes patients treated with radiation 
Abbreviations: IMRT = Intensity Modulated Radiation Therapy; 3DCRT = 3 Dimensional 
Conformal Radiation Therapy; PSA = Prostate Specific Antigen; TURP = Transurethral 
Resection of the Prostate; CI = Confidence Interval 
 
 
In unadjusted analysis, clinical stage (Hazard Ratio 3.60, 95% CI 2.34-
5.53, p<.001), Gleason score (Hazard Ratio 2.19, 95% CI 1.66-2.90, p<.001), 
and pretreatment PSA (Hazard Ratio 1.42, 95% CI 1.09-1.83, p= .009) predicted 
BDFS, but treatment modality did not (p=.74). After adjustment, clinical stage 
(Hazard Ratio 2.42, 95% CI 1.52-3.85, p<.001) and Gleason score (Hazard Ratio 
2.02, 95% CI 1.46-2.79, p<.001) were predictive of BDFS, but the impact of 
treatment modality (Hazard Ratio 0.62, 95% CI 0.38-1.03, p=.06, favoring IMRT) 
and pretreatment PSA (Hazard Ratio 1.20, 95% CI 0.92-1.56, p=.19) did not 
achieve statistical significance. Additionally, race (p=.22) and age (p=.58) did not 
affect biochemical disease free survival on multivariable analysis. 
 An unadjusted and adjusted analysis were performed on the MSK poor 
prognosis group as well (Table 4).  
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Table 4. Unadjusted and Adjusted Analysis of Patient Characteristics 
and Biochemical Failure for MSK Poor Prognosis Subset 
Clinical 
Parameter† 
Unadjusted 
p value 
Unadjusted 
Hazard 
Ratio 95% CI 
Adjusted 
p value 
Adjusted 
Hazard 
Ratio 95% CI 
              
Age 0.003 0.43 0.24-0.76 0.08 0.96 0.92-1.00 
Race* 0.81 1.08 0.56-2.08       
Prior TURP 0.79 1.21 0.29-5.15       
Clinical 
Stage 0.02 2.02 1.11-3.68       
Gleason 
Score (total) 0.04 1.69 1.03-2.80 0.001 2.20 1.36-3.57 
Pretreatment 
PSA 0.41 0.87 0.62-1.22       
Treatment 
Modality <.001 0.36 0.20-0.63 0.006 0.39 0.20-0.77 
Method of 
Radiation†† 0.12 0.45 0.16-1.22       
Treatment 
Site††† 0.28 3.02 
0.41-
22.40       
Hormonal 
Therapy 0.08 0.60 0.34-1.06       
*only Whites and African Americans were compared in this analysis 
 
† Coding of clinical parameters: Age (continuous, per year), Race (reference = white), Prior 
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TURP (reference = no TURP), Clinical Stage (T1-T2a versus T2b-T2c versus T3a-T3b, 
reference = T1-T2a), Gleason Score (<7 versus 7 versus >7, reference = <7), Pretreatment 
PSA (continuous, per ng/mL increment), Treatment Modality (reference = RP), Method of 
Radiation (reference = 3DCRT + IMRT), Treatment Site (reference = Lawrence & Memorial 
Hospital), Hormonal Therapy (reference = no hormonal therapy)   
††only 3DCRT+IMRT and IMRT alone were compared in this analysis 
†††only includes patients treated with radiation 
 
Abbreviations: IMRT = Intensity Modulated Radiation Therapy; 3DCRT = 3 Dimensional 
Conformal Radiation Therapy; PSA = Prostate Specific Antigen; TURP = Transurethral 
Resection of the Prostate; CI = Confidence Interval 
 
 
In unadjusted analysis, age (Hazard Ratio 0.43, 95% CI 0.24-0.76, 
p=.003), clinical stage (Hazard Ratio 2.02, 95% CI 1.11-3.68, p=.02), Gleason 
score (Hazard Ratio 1.69, 95% CI 1.03-2.80, p=.04), and treatment modality 
(Hazard Ratio 0.36, 95% CI 0.20-0.63, p<.001) were significant predictors of 
biochemical disease free survival. In multivariable analysis, only Gleason score 
(Hazard Ratio 2.20, 95% CI 1.36-3.57, p=.001) and treatment modality (Hazard 
Ratio 0.39, 95% CI 0.20-0.77, p= .006) predicted biochemical failure. The p value 
for age (p=.08) did not reach statistical significance. 
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Discussion 
 
We conducted a retrospective cohort study to investigate whether RP or 
IMRT, plus hormonal therapy if indicated, is associated with improved 
biochemical disease free survival compared to the alternative modality. Our 
results suggest that there is no difference in outcome for patients with a favorable 
prognosis, but patients with a poor prognosis and some patients with an 
intermediate prognosis (those in the NCCN intermediate prognosis group) may 
have improved outcomes when treated with IMRT and hormonal therapy. 
Patients in the IMRT cohort had more advanced and aggressive disease 
than their RP counterparts, as indicated by the significantly higher Gleason 
scores, pretreatment PSA values, and amount of extracapsular (T3) disease at 
presentation. This explains the change in unadjusted (p=.74) versus adjusted 
(p=.06) p values associating treatment modality to outcome (Table 3) and should 
be considered in the interpretation of our results. 
Interestingly, the rates of BDFS seen in the RP cohort are similar to rates 
seen in other studies20, 25 and are marginally better than those predicted by the 
Kattan nomogram for post-RP patients;71 in the MSK favorable, intermediate, and 
poor prognostic groups, the Kattan nomogram-predicted versus our observed 
five-year biochemical disease free survival rates (respectively) are 90.8% versus 
95.1%, 81.8% versus 86.7%, and 43.8% versus 53.8%.  
Our rates of BDFS for patients treated with IMRT are similar to those 
reported in other series,20, 25, 61 including the Kattan nomogram-predicted rates 
 32 
for post external beam radiation patients,72 with the exception of patients in the 
poor prognostic group subsets of the IMRT cohort. These patients may have 
better outcomes than those in some previously reported series. This finding may 
be attributable to our study including patients treated to at least 72 Gy, which 
other studies suggest yields better outcomes than doses less than 72 Gy. 
Kupelian et al. found that, on unplanned subgroup analysis, patients with an 
unfavorable prognosis (clinical stage ≥T2b, Gleason Score ≥7, or pretreatment 
PSA >10) have significantly higher biochemical disease free survival rates when 
treated with external beam radiation therapy to ≥72 Gy as opposed to RP, but a 
significantly worse biochemical disease free survival when treated with external 
beam radiation therapy to <72 Gy compared to RP.22 Additional support for 
treating patients to doses ≥72 Gy comes from a randomized trial comparing 
external beam radiation therapy of 78 Gy to external beam radiation therapy of 
70 Gy, which showed improved five-year biochemical disease free survival in the 
78 Gy arm (78% vs. 68%, p=.03). This result was even more striking when 
patients with a pretreatment PSA of >10 ng/mL were examined (72% vs. 43%, 
p=.01), suggesting that patients with an unfavorable prognosis derive the most 
benefit from dose escalation.39 Another prospective trial randomized patients to 
external beam radiation therapy to a dose of either 68 Gy or 78 Gy.  Patients in 
the 78 Gy arm showed significantly higher disease free survival rates than 
patients in the 68 Gy arm.32 A similar result was seen by Zelefsky et al., who 
noted improved BDFS in patients treated to 81.0 Gy, as compared to those 
treated to 64.8 Gy.33 Dose escalation could explain why our study found an 
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improvement in BDFS in the poor prognosis subsets of the IMRT cohort, relative 
to the RP cohort, as no other previous study utilized radiation doses as high as 
those used in our study. 
The higher biochemical disease free survival seen in IMRT patients with a 
poor prognosis could also be attributable to the hormonal therapy given in 
conjunction with radiation, as hormonal therapy is theorized to eliminate residual 
local disease in patients treated with external beam radiation therapy. Hormonal 
therapy has been shown in prospective trials to improve overall survival and 
disease-specific survival in poor prognosis patients, and some intermediate 
prognosis patients, treated with external beam radiation therapy, as illustrated by 
RTOG 8610 and a prospective study published by Bolla et al (discussed in the 
introduction).40, 41, 45, 47 We unfortunately do not have the capability to determine 
whether the improvement in BDFS seen in patients who received IMRT is the 
result of increased dose, the presence of hormonal therapy, the combination of 
both, or other reasons. 
The novel definitions of biochemical disease free survival used in this 
paper do not alter the significance of the result. Our definition of post-RP failure 
is more stringent than most others used in past retrospective studies,11, 19-25, 51 
and the definition of post-IMRT failure used in this study has a higher sensitivity 
for failure than that used in other retrospective studies, with the exception of the 
review published by Keyser et al.19, 51 Therefore, it is extremely unlikely that the 
novel definitions of failure utilized in this study could account for the improved 
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outcome seen in IMRT patients with an intermediate or poor prognosis relative to 
their RP counterparts.  
 Strengths of our study include a blind reabstraction to ensure reliability of 
data collection and the utilization of recommended definitions of biochemical 
failure. Additionally, the data was analyzed with the ASTRO and AUA 
recommended definitions of failure using standard prognostic group schemes. 
Limitations of our study include the restrictions of a retrospective analysis. 
Although we tried to account for all possible confounding factors, it is possible 
that we did not account for a patient characteristic that contributes to outcome. 
Despite the fact that we have a reasonable sample size, analysis of individual 
subgroups of patients, although preplanned, was conducted on a smaller group 
of patients. As a result, certain known adverse prognostic factors did not achieve 
statistical significance when assessing their impact on biochemical disease free 
survival.  
In addition, had the median follow up of our study been longer, we may 
have been able to use a more robust outcome measure in place of BDFS, such 
as overall survival, disease-specific survival, or metastasis free survival. Also, we 
can not conclusively say that five-year BDFS rates in each cohort would correlate 
with ten-year BDFS rates, the latter of which would also represent a more 
meaningful outcome measure. 
 The variable definitions of failure that we utilized for RP and IMRT 
patients represent an unavoidable limitation of the study. Although we used 
definitions of failure recommended by the American Urological Association and 
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the American Society for Therapeutic Radiology and Oncology in their respective 
consensus statements,54, 55 we recognize that the implications of these definitions 
of failure are in fact different.  We feel that there is no single definition of 
biochemical failure that is appropriate for patients receiving a radical 
prostatectomy and patients receiving external beam radiation therapy, because 
after successful radical prostatectomy, no prostate tissue remains in the body 
and therefore the PSA should be undetectable (or nearly undetectable, as 
indicated by the 0.2 ng/mL threshold set by the American Urological 
Association).55 After external beam radiation therapy, however, viable prostate 
tissue may remain, and therefore such a definition of failure would be 
inappropriate. After vigorous deliberation, the American Society for Therapeutic 
Radiology and Oncology decided that the appropriate definition of failure in such 
cases should be “PSA nadir + 2 ng/mL”.54 In addition, the American Urological 
Association recognizes that patients treated by external beam radiation therapy 
will be evaluated with a different definition of failure: “The Panel recommends the 
use of the American Society for Therapeutic Radiology and Oncology criteria for 
patients treated with radiation therapy”.55 In addition, six of the eight retrospective 
studies cited in this manuscript comparing radical prostatectomy to external 
beam radiation therapy have used varying definitions of biochemical failure. 
Although a single definition of failure would have been optimal, variable post-
treatment prostate physiology precluded us from using such a definition in our 
study.  
 36 
 Another limitation of our study pertains to the fact that 37% of patients in 
the favorable prognosis group of the IMRT cohort received hormonal therapy, as 
hormonal therapy is generally not indicated for this group of patients. Because 
we chose biochemical disease free survival as the endpoint of the study, and 
because hormonal therapy significantly reduces PSA levels, the results of our 
trial could be biased in favor of the IMRT cohort, particularly the value obtained 
by the log-rank test comparing Kaplan Meier curves.  
Additionally, it is possible that the improved outcome seen in the IMRT 
subset of the NCCN intermediate prognosis group and both the MSK and NCCN 
poor prognosis groups (relative to the RP subset) is secondary to the transient 
PSA-lowering effect of hormone therapy. As already discussed, this could 
certainly affect the p value obtained from the log-rank test comparing survival 
curves. However, five-year BDFS rates were significantly higher in IMRT patients 
when compared to RP patients, and any testosterone-lowering effects caused by 
hormonal therapy will have long dissipated by five years post-therapy (or 3-4 
years after the conclusion of hormonal therapy). Therefore, the significant 
difference in five-year BDFS rates between the RP and IMRT cohorts likely 
reflects the established long-term benefit of hormonal therapy on intermediate 
and poor prognosis group patients treated with external beam radiation therapy, 
rather than a statistical artifact. 
Zelefsky et al. have reported improved biochemical disease free survival 
and distant metastases free survival rates with dose escalation beyond 75.6 Gy 
in patients with an intermediate and poor prognosis,73 indicating that further dose 
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escalation may be of benefit to such patients. We are now using image-guided 
IMRT to dose escalate above 80 Gy, particularly in patients with an intermediate 
or poor prognosis. 
In conclusion, biochemical disease free survival rates in patients with 
prostate adenocarcinoma appear to be related to intrinsic tumor characteristics 
such as clinical stage, Gleason score, and pretreatment PSA. In addition, for 
patients with a poor prognosis, and some patients with an intermediate 
prognosis, IMRT to a dose greater than 72 Gy administered with hormonal 
therapy may yield improved BDFS when compared to radical prostatectomy.  
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